- Stocks
- Healthcare
- NYSE: MRK

Price (delayed)

$127.11

Market cap

$321.92B

P/E Ratio

907.93

Dividend/share

$2.96

EPS

$0.14

Enterprise value

$350.14B

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the

The gross profit has grown by 5% year-on-year

MRK's gross margin is up by 3.7% year-on-year

The EPS has plunged by 98% YoY and by 92% from the previous quarter

The net income has dropped by 97% year-on-year and by 92% since the previous quarter

What are the main financial stats of MRK

Market
Valuations
Earnings

Shares outstanding

2.53B

Market cap

$321.92B

Enterprise value

$350.14B

Price to earnings (P/E)

907.93

Price to book (P/B)

8.57

Price to sales (P/S)

5.36

EV/EBIT

115.82

EV/EBITDA

50.78

EV/Sales

5.82

Revenue

$60.12B

EBIT

$3.02B

EBITDA

$6.9B

Free cash flow

$9.14B

Per share
Balance sheet
Liquidity

EPS

$0.14

Free cash flow per share

$3.6

Book value per share

$14.83

Revenue per share

$23.7

TBVPS

$26.59

Total assets

$106.68B

Total liabilities

$69.04B

Debt

$35.06B

Equity

$37.58B

Working capital

$6.47B

Debt to equity

0.93

Current ratio

1.25

Quick ratio

0.68

Net debt/EBITDA

4.09

Margins
Efficiency
Dividend

EBITDA margin

11.5%

Gross margin

73.2%

Net margin

0.6%

Operating margin

3.9%

Return on assets

0.3%

Return on equity

0.9%

Return on invested capital

4.4%

Return on capital employed

3.7%

Return on sales

5%

Dividend yield

2.33%

DPS

$2.96

Payout ratio

2,114.3%

How has the Merck stock price performed over time

Intraday

-0.84%

1 week

-1.66%

1 month

4.81%

1 year

19.64%

YTD

16.59%

QTD

16.59%

How have Merck's revenue and profit performed over time

Revenue

$60.12B

Gross profit

$43.99B

Operating income

$2.36B

Net income

$365M

Gross margin

73.2%

Net margin

0.6%

MRK's net margin has dropped by 98% year-on-year and by 92% since the previous quarter

The net income has dropped by 97% year-on-year and by 92% since the previous quarter

Merck's operating income has plunged by 87% YoY and by 70% from the previous quarter

Merck's operating margin has shrunk by 87% YoY and by 70% QoQ

What is Merck's growth rate over time

What is Merck stock price valuation

P/E

907.93

P/B

8.57

P/S

5.36

EV/EBIT

115.82

EV/EBITDA

50.78

EV/Sales

5.82

The EPS has plunged by 98% YoY and by 92% from the previous quarter

The price to book (P/B) is 29% higher than the 5-year quarterly average of 6.7 and 27% higher than the last 4 quarters average of 6.8

Merck's equity has decreased by 18% YoY and by 9% from the previous quarter

How efficient is Merck business performance

The company's return on assets has shrunk by 98% YoY and by 93% QoQ

Merck's ROE has plunged by 97% YoY and by 92% from the previous quarter

The ROIC has shrunk by 84% YoY and by 65% QoQ

The ROS has plunged by 83% YoY and by 65% from the previous quarter

What is MRK's dividend history

DPS

$2.96

Dividend yield

2.33%

Payout ratio

2,114.3%

Recent dividends

How did Merck financials performed over time

The total assets is 55% more than the total liabilities

MRK's quick ratio is down by 27% year-on-year and by 18% since the previous quarter

The current ratio has contracted by 15% YoY and by 9% from the previous quarter

MRK's debt is 7% smaller than its equity

The debt to equity has grown by 39% YoY and by 9% from the previous quarter

Merck's equity has decreased by 18% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.